Bone loss and new vertebral fractures during treatment with romosozumab: a case-report.
Arch Osteoporos
; 19(1): 10, 2024 01 19.
Article
en En
| MEDLINE
| ID: mdl-38238593
ABSTRACT
PURPOSE:
This study aimed to illustrate the possibility of an unfavorable response to treatment with the anabolic agent romosozumab for patients with severe osteoporosis and to discuss explanations for treatment failure.METHODS:
Dual-energy x-ray absorptiometry (DXA) including vertebral fracture assessment (VFA) and X-rays of the thoracolumbar spine was used to assess bone mineral density (BMD) and the presence of vertebral fractures before and after treatment with romosozumab.RESULTS:
Our patient developed a decrease in the BMD of the hip, two incident new vertebral fractures, and worsening of one prevalent vertebral fracture during 1 year treatment with romosozumab. We have not detected non-adherence, there was no pretreatment with anti-resorptives, and we observed no signs of secondary osteoporosis and/or comorbidities.CONCLUSION:
As the number of patients treated with romosozumab is rising, it becomes more likely that more patients will be found with new fractures and/or an unfavorable BMD response. Probably, the unfavorable response is a (bad) chance finding, but we think it is crucial for clinicians and patients to exclude nonadherence, new comorbidities and pretreatment with anti-resorptives as explanation in these patients.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Osteoporosis
/
Enfermedades Óseas Metabólicas
/
Fracturas de la Columna Vertebral
/
Fracturas Óseas
/
Anticuerpos Monoclonales
Límite:
Humans
Idioma:
En
Revista:
Arch Osteoporos
Año:
2024
Tipo del documento:
Article
País de afiliación:
Países Bajos